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ABSTRACT Previous work has shown that mammalian cells
that carry unstably amplified genes for dihydrofolate reductase
(DHFR) gradually lose the amplified DHFR genes when grown in
the absence of the DHFR inhibitor methotrexate (MTX). Unsta-
bly amplified genes occur on small acentric chromosomes called
double minutes (DMs) or even smaller chromatin fragments, in
contrast to stably amplified genes, which reside in centromere-
containing chromosomes. We have found that the rate of loss of
the unstably amplified DHFR genes can be greatly increased by
growing the cells in the presence of a nonlethal concentration of
hydroxyurea. For example, in one MTX-resistant subline studied,
=90% of the original DHFR gene dosage is lost in 25-30 cell dou-
blings in the absence of MTX. The same degree of loss is achieved,
however, in <4 doublings if cells are grown in the presence of 50
pM hydroxyurea. This new effect of hydroxyurea does not appear
to be due to changes in plating efficiency or selective cytotoxicity.
In particular, no increase in cell death occurs at 50 JIM hydroxy-
urea, and cells continue to multiply, albeit '/2 to 2/3 as fast as in the
absence of hydroxyurea. The ability to selectively accelerate the
loss of amplified genes from mammalian cells as shown in the
present work may have important implications both for the prob-
lem of drug resistance in cancer chemotherapy and for curing
mammalian cells of extrachromosomally maintained DNA ge-
nomes of pathogenic viruses.
Mammalian cells have been shown to acquire resistance to a
dihydrofolate reductase (DHFR) inhibitor, methotrexate (MTX),
either through an amplification of the DHFR gene, which leads
to overproduction of the target DHFR enzyme (1-7), through
mutations rendering the DHFR enzyme less sensitive to MTX,
or through mutations decreasing MTX uptake by cells (1). Of
these causes of MTX resistance, DHFR gene amplification ap-
pears to be the most frequent one under a variety of experi-
mental conditions (1-7).
Amplified chromosomal regions other than the DHFR gene
domain also occur in a wide variety of eukaryotic cells, usually
as a result of in vivo or in vitro selection for specific properties,
such as tumorigenicity (5, 6, 8) or resistance to a cytotoxic drug
(1, 7, 9), but also in the course of normal development (10).
Amplified chromosomal regions occur either within the ma-
jor cellular chromosomes where they are frequently recogniz-
able as karyotypic abnormalities called "homogeneously stain-
ing regions" or as small acentric chromosomes called "double
minutes" (DMs) (1, 8-11). Unlike stably amplified genes in ho-
mogeneously staining regions, which are retained for many
generations in the absence of a relevant selection pressure, the
unstably amplified genes in acentric DMs or smaller chromatin
fragments are gradually lost from cells in the absence of se-
lection pressure, at least in part because of the absence of func-
tioning centromeres in DMs (1-6, 11).
It was recently reported that phorbol 12-myristate 13-acetate
(PMA), a noncytotoxic, nonmutagenic phorbol ester tumor pro-
moter, greatly increases the incidence of mouse cells with am-
plified DHFR genes under conditions of cytotoxic selection for
resistance to MTX (4). Subsequent work by Tlsty et al. (12) has
confirmed this result and in addition showed that transient cy-
totoxic treatment of mammalian cells (with hydroxyurea or ul-
traviolet light) before selection for MTX resistance also leads to
an increased incidence of cells with amplified DHFR genes (12,
13). Noncytotoxic tumor promoters other than PMA as well as
mitogenic hormones, such as insulin or epidermal growth fac-
tor, have also been shown recently to greatly increase the in-
cidence of MTX resistance due to DHFR gene amplification
(14). These findings have provided indirect support for an ear-
lier hypothesis that one pathway of carcinogenesis and tumor
progression may operate through a generalized increase in the
frequency of disproportionate DNA replication, resulting in ac-
celerated gene amplification (15). Targets for such "facilitated"
gene amplification may include genes responsible for the initial
stages of carcinogenesis or other genetic loci-for example, genes
influencing metastatic potential or immunosuppressive prop-
erties of evolving tumor cells (5, 6, 8, 11, 15-17). Regardless
of which of the suggested mechanisms of facilitated gene am-
plification is the correct one, it is clear that the probability of
either gene amplification per se or survival of "nascent" cells
bearing amplified genes can vary dramatically at least in vitro,
depending on the conditions of selection (4, 12-14).
In several situations (for example, in cancer chemotherapy),
one would like to minimize the probability of either the emer-
gence or the persistence of cells with undesirable amplified
genes. One way to approach this problem is to look for ways to
increase the probability of loss of already amplified genes and
to do so under otherwise noncytotoxic conditions.
We report here that when mouse cells bearing unstably am-
plified DHFR genes are grown in the presence of nonlethal
concentrations of hydroxyurea, the rate of loss of the DHFR
genes from these cells is greatly increased.
MATERIALS AND METHODS
Cell Lines. Two cell lines were used: R.3, a subline of mouse
3T6 cells selected for resistance to 0.3 AM MTX (4), and R500,
a subline of 3T6 cells selected for resistance to 250 ,M MTX
(a gift from R. Kaufman and R. Schimke). The cells were main-
tained in Dulbecco's modified Eagle's medium (GIBCO) sup-
plemented with penicillin/streptomycin, exhaustively dialyzed
10% calf serum (4), and either 0.3 ,M MTX (for R.3 cells) or
250 AM MTX (for R500 cells).
Abbreviations: DHFR, dihydrofolate reductase; MTX, methotrexate;
DMs, double-minute chromosomes; PMA, phorbol 12-myristate 13-
acetate; cis-DDP, cis-diamminedichloroplatinum(II).
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FIG. 1. Loss of unstably amplified DHFR gene
as a function of cumulative cell doublings in the i
control) and in the presence of either cis-DDP (n,
8 44), or hydroxyurea (0, 50 AM). (A) R.3 cells (a
selected for resistance to 0.3 pM MTX; ref. 4) wer
presence of 0.3 pM MTX. To start the experiment, c
by gentle trypsinization, counted in a hemacytomete
four 10-cm plates (Falcon) at 1 x 105 cells per plate i
but with undialyzed calfserum and withoutMTX.
fluent monolayers, cells in one of four plates in e
seeded onto four new plates under the same conditi
three plates were used for isolation of the total nuc
dosages of theDHFR gene were determined by DN
bridization. (Inset) Example of dot hybridization
bridization with the DHFRcDNA probe; rows 7-12
the P*-globin cDNA probe. Dots c5, c8, and cli a
loading (data not shown). Dots al-fl and a7-f7:Dh
dosages, respectively, for R.3 cells at the time of rei
containing 0.3 IA4 MTX. Dots a2-a6 and a7-a12
gene dosages, respectively, for the MTX-sensitive
("single-copy" control forDHFR). For the remainin
8-12 represent DHFR and globin gene dosages, r
DNA Isolation and DNADNA Dot Hybridization. Cell
monolayers were rinsed with 0.14 M NaCl/5 mM Na Hepes
(pH 7.5), then scraped with a rubber policeman into 0.5% Non-
idet P-40/5 mM Na2EDTA/5 mM Na Hepes, pH 7.5. The ly-
sate was homogenized by four strokes of a Dounce homoge-
nizer with a loose-fitting pestle and then centrifuged at 2,000
X g for 5 min. Purification of DNA from the pellet of crude
nuclei was carried out as described (4). In some experiments
DNA was purified in parallel from both whole cells and isolated
nuclei. Cell-population doubling times were deduced from the
number of cells initially seeded and the number of cells at con-
fluence at each passage. Relative dosage of the DHFR gene
(defined as a ratio of the DHFR copy number in MTX-resistant
cells to that in MTX-sensitive unselected 3T6 cells) was deter-
mined by a DNA-DNA dot-blot hybridization as described (4,
18), except that a dot-blot manifold (Schleicher & Schuell) was
used, and quantitation of dot hybridization patterns was carried
out by cutting out and assaying individual dots of [3P]DNA (this
procedure yields more accurate results than visual comparisons
of dot intensities; data not shown). The 32P-labeled hybridiza-
tion probes used were a cloned mouse DHFRcDNA (pDHFR11;
ref. 19; a gift from R. Schimke) and a cloned mouse Bmaij-globin
cDNA (pCRI-M9; ref. 20; donated by V. Volloch).
RESULTS
Search for Noncytotoxic Treatments That Accelerate Loss
of Amplified Genes from Mammalian Cells: Strildng Effect of
Hydroxyurea. Our strategy was to grow unstably MTX-resis-
tant mouse cells in the absence of MIX and to monitor the de-
crease of their DHFR gene dosage as a function of cumulative
cell doublings (population doublings) in the presence of a pu-
tative "gene loss-inducing" agent (Fig. 1). An important cri-
terion used in the search for such an agent was that its effective
concentration had to be nonlethal for cells on prolonged ex-
posure. Therefore the concentration of each of the compounds
to be tested in the DHFR gene loss assay (Fig. 1) was first op-
timized by growing the cells for a number of generations in the
presence of different concentrations of the compound to be
tested and then choosing the concentration that neither in-
creased cell death nor slowed cell multiplication more than 2-
fold (Fig. 2). Hydroxyurea, which happened to be the third agent
tested, produced a striking effect (Figs. 1 and 3-5). Other com-
pounds or treatments, some of which are known to facilitate the
30 35 40 loss of plasmids from bacterial cells (21-25), could be tested to
compare their effect on the rate of the DHFR gene loss with
that of hydroxyurea.
Les from mouse cells Mouse R.3 cells (a subline of 3T6 cells selected for resistance
absence of MTX (a to 0.3 pM MTX that contains "15 copies of the unstably am-
0.17 ,uM), PMA (a, plified DHFR gene per haploid genome; see refs. 4 and 14) grown
subline of 3T6 cells in the absence of MIX gradually lose their extra DHFR genes,
e maintained in the with -90% of the DHFR gene dosage lost after 25-30 cell dou-
:ellswere suspended blings (the fourth passage in MTX-free medium) (Fig. 1A). The
ndthesamemedium noncytotoxic phorbol ester tumor promoter PMA (4, 26) at 8
Onformation of con- uM and the cytotoxic drug cis-diamminedichloroplatinum(II)
aach series were re- (cis-DDP) (27, 28) at 0.17 pM had little or no effect on the rate
ions. The remaining of decrease in the DHFR gene copy number (Fig. 1A). In strik-
eADNAdot-blothy- ing contrast, when an analogous parallel experiment was car-iata. Rows1t-6 hy- ried out in the presence of 50 gM hydroxyurea, =90% of the
!, hybridization with
Ire artefacts ofDNA
(FR and globin gene
moval from medium
1: DHFR and globin
unselected 3T6 cells
gdots, rows 2-6 and
espectively, for suc-
cessive passages in the absence of MTX (columns b and e) and in the
absence of MTX and presence of either 0.17 pM cis-DDP (column c), 8
,uM PMA (column d), or 50 PM hydroxyurea (column f). The curves in
A andB were derived directly from the dot hybridizationdata (inset and
analogous data not shown). (B) R500 mouse cells resistant to 250 jiM
MTX (a gift from R. Kaufman and R. Schimke) were grown and ana-
lyzed as described in A for R.3 cells.
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Proc. Natl. Acad. Sci. USA 80 (1983)
35
30
25
20
15
10
u,
be
-
vs
5
A
I- .
Cell Biology: Snapka and Varshavsky
35[ B
2
1
11
0 5 10 15 20 25 30 35 40 45 50 55
Days in culture
FIG. 2. Growth of R.3 cells (A) and R500 cells (B) through five pas-
sages in the absence ofMTX (e) and in the absence ofMTX and pres-
ence of either cis-DDP (n, 0.17 MM), PMA (A, 8 uM), or hydroxyurea
(o, 50 MM).
DHFR gene dosage was lost in less than four cell doublings (first
passage in MTX-free medium) (Fig. 1A). Similar results were
obtained with another line of MTX-resistant cells, R500 (a gift
from R. Kaufman and R. Schimke). These cells are resistant to
250 AtM MTX and contain =170 copies of the DHFR gene per
haploid genome; most but not necessarily all of these extra DHFR
genes are amplified unstably (ref. 29; Fig. 1B; data not shown).
Hydroxyurea at Concentrations That Accelerate Loss of
DHFR Genes Allows Continued Cell Multiplication. Cells of
both sublines continued to multiply in the presence of 50 AtM
hydroxyurea (1/2 to 2/3 as fast as in the absence of hydroxyurea),
and there was no detectable increase in cell death in the pres-
ence of hydroxyurea as compared to the control medium (Fig.
2; data not shown). An apparently lower growth rate of cells in
the presence of 50 ,uM hydroxyurea is due at least in part to
a larger surface area, that each cell occupies on a plate in the
presence of 50 AM hydroxyurea (data not shown). The result
is that the cell monolayers become confluent approximately two
doublings earlier than their counterparts grown in the absence
of hydroxyurea (Fig. 4A). The larger surface area of cells grown
in 50 AM hydroxyurea is due to a hydroxyurea-mediated met-
abolic disturbance that leads to an increased cell volume (30).
The concentration of hydroxyurea used throughout this work
(50 ,M) was chosen to maximize the rate of DHFR gene loss
without decreasing cell viability and only moderately decreas-
ing growth rate of cells (Fig. 2). Concentrations of hydroxyurea
significantly below 50 AM were much less effective in accel-
erating the loss of the DHFR genes (Fig. 3). On the other hand,
concentrations of hydroxyurea significantly higher than 50 pM
do result in significant cytotoxicity after prolonged exposure
(data not shown).
Hydroxyurea Effect at Low Cell-Population Doublings. To
follow the loss of the DHFR genes between one and four cell
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FIG. 3. Rate of loss of unstably amplified DHFR genes as a func-
tion ofhydroxyurea concentration. For each experimental series, R500
cells maintained in the presence of 250 HM MTX were removed from
their plates by trypsinization and reseeded at 1 x 105 cells per plate
onto four 10-cm plates containing the same medium but without MTX.
When the cells in each series reached confluence, one plate from the set
of four was trypsinized, the cells were counted and passed to four new
plates at 1 x 105 cells per plate, and the remaining three plates were
harvested and processed for isolation of nuclear DNA. *, No hydroxy-
urea; A, 10 ,uM hydroxyurea; o, 25 ,uM hydroxyurea; o, 50 pM hy-
droxyurea. Data from two separate dot-blot hybridizations with the same
DNA samples are shown.
doublings, R500 cells maintained in the presence of 250 ,uM
MTX were plated at 1 x 105 cells per plate in the absence of
MTX. Medium in half of the plates was made 50 ,uM in hy-
droxyurea. Cultures in both hydroxyurea-lacking and hydroxy-
urea-containing media reached confluence at the same time,
the hydroxyurea-treated cells having undergone approximately
five population doublings and the untreated cells approxi-
mately seven doublings (Fig. 4A). The striking effect of hy-
droxyurea on the rate of loss of the DHFR genes from cells in
the course of this single-passage experiment is shown in Fig.
4B. Considering the ways in which unstably amplified genes
are thought to be lost from cells (1-6), it is interesting that the
DHFR gene dosage in the hydroxyurea-treated cells continued
to decrease between days 10 and 12, a period when the cells
are at the plateau of their growth curve (Fig. 4B; cf. Fig. 4A).
Rate of Hydroxyurea-Accelerated DHFR Gene Loss from
R500 Cells Is the Same Whether Measured with Nuclear or
Whole Cell DNA Samples. To see if the hydroxyurea effect is
due to an increased probability of postmitotic partitioning of
DHFR gene-containing DMs into the cytoplasm through for-
mation of micronuclei [a known pathway of DM loss (1)], we
have monitored the DHFR gene dosage decrease at low cell-
population doublings using both nuclear and whole cell DNA
samples in a series of parallel measurements. The results ob-
tained (Fig. 5) clearly did not significantly depend on the way
DNA was isolated (either from crude nuclei or from whole cells).
Although the data of Fig. 5 are consistent with "nonpartition-
ing" mechanisms of the hydroxyurea effect, they are insuffi-
cient to preclude the "partitioning" mechanisms, because sev-
eral interpretations (for example, cosedimentation of nuclei and
micronuclei in our preparations or rapid in vitro degradation of
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FIG. 4. Hydroxyurea-accelerated loss of DHFR genes during one
passage of R500 cells prior to confluence. R500 cells were seeded at 1
x 105 cells per 10-cm plate in the absence of MTX (e, control) or in the
absence of MTX and in the presence of 50 utM hydroxyurea (o). Cell
growth (A) and relative DHFR gene dosages (B) were monitored as de-
scribed. Lower density of R500 cells at confluence in the presence of
hydroxyurea is due to their increased size.
micronuclear DNA in the cytoplasm) are still compatible with
the data.
Stably Amplified DHFR Genes Are Not Lost in the Pres-
ence of Hydroxyurea. When mouse L1578Y-R cells (a gift from
J. Bertino), which carry --350 stably amplified DHFR genes
per haploid genome (4, 31), were grown in the absence of MTX
and in the presence of either 25 or 50 ,uM hydroxyurea for six
population doublings, there was no detectable decrease in the
DHFR gene dosage in these cells (data not shown). Thus hy-
droxyurea does not have a dramatic effect on stably amplified
DHFR genes, at least during relatively short courses of treat-
ment.
DISCUSSION
Two major questions are raised by our results: (i) what is the
mechanism of the hydroxyurea effect (Figs. 1 and 3-5) and (ii)
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FIG. 5. Effect of hydroxyurea on DHFR gene dosage in R500 cells
at low population doublings: identical results with DNA from whole
cells and isolated nuclei. R500 cells maintained in the presence of 250
,.MMTX were trypsinized and reseeded at 1 x 106 cells per plate (eight
10-cm plates) and at 4 x 106 cells per plate (eight 10-cm plates) in me-
dium withoutMTX and with or without 50 M hydroxyurea. When the
cells of each series reached confluence, cells in two plates were tryp-
sinized to determine cell numbers, and three plates were processed for
isolation of nuclear DNA; the remaining three plates were used to iso-
late DNA from whole cells (detached from plates by trypsinization and
washed free from the medium). No hydroxyurea, nuclear DNA (e); 50
gM hydroxyurea, nuclear DNA (o); double circles represent corre-
sponding data for DNA from whole cells.
what possible uses could this new effect be put to?
The absence of significant cytotoxicity of 50 ,tM hydroxy-
urea toward cells from lines bearing widely different numbers
of amplified DHFR genes (see above) argues strongly against
any mechanism for the hydroxyurea effect in which hydroxy-
urea preferentially suppresses growth of those cells that have
higher than average numbers of the amplified DHFR genes.
One possible mechanism of the hydroxyurea effect may op-
erate by increasing the probability of postmitotic partitioning
of DHFR gene-containing DMs into the cytoplasm through for-
mation of micronuclei [a known pathway of DM loss (1-6)]. Al-
though our results are compatible with such a partitioning
mechanism, they add a constraint that the micronuclear DHFR
DNA in the cytoplasmic compartment should be degraded rap-
idly in vivo to account for indistinguishable results of moni-
toring the DHFR gene loss with either nuclear or whole-cell
DNA samples (Fig. 5).
Other possibilities are that hydroxyurea preferentially in-
hibits replication [or decatenation (32)] of unstably amplified
DHFR genes or induces their preferential degradation. Al-
though it is likely that the gene loss-enhancing effect of hy-
droxyurea is mediated by its specific inhibition of the enzyme
ribonucleoside diphosphate reductase (33, 34), a component of
the replication fork (35), no direct evidence is available on this
point. Use of other specific inhibitors of ribonucleoside di-
phosphate reductase (36) is one way to address this question.
Furthermore, it is likely that unstably amplified genes other
than DHFR are also subject to accelerated loss in the presence
of hydroxyurea.
Transient treatments of mammalian cells with cytotoxic con-
centrations of hydroxyurea are known to increase the fre-
quency of the DHFR gene amplification, apparently by in-
creasing the probability of disproportionate DNA replication
(12, 13); a possible relationship of this phenomenon to the new
Proc. Natl. Acad. Sci. USA 80 (1983)
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effect of nonlethal hydroxyurea concentrations on the frequen-
cy of loss of the DHFR genes remains to be investigated.
Although hydroxyurea is a widely used antineoplastic drug,
it is not understood why it is relatively effective for certain can-
cers, such as chronic granulocytic leukemia or polycythemia vera
(37), but not for many other malignant tumors. Concentrations
of hydroxyurea in patients' tissues considered to be therapeu-
tically useful (cytotoxic) are at least an order of magnitude higher
than the hydroxyurea concentration used in the present work
(50 ILM) (37). Hydroxyurea is also known to be a potent tera-
togen (38, 39). Because transient amplification of specific genes
has been shown to constitute a part of normal development in
at least some of the higher eukaryotic species (10), and because
many cancers are known to be associated with gene amplifi-
cation (1, 4-8, 39), the new effect of hydroxyurea described
above may be relevant to both teratogenic and antineoplastic
activities of hydroxyurea.
What are the potential applications of the ability to selec-
tively accelerate the loss of unstably amplified genes from
mammalian cells?
Previous studies have shown that the incidence of cells bear-
ing amplified genes under conditions of cytotoxic selection can
vary more than 100-fold and depends on either the presence of
mitogenic substances (hormones or tumor promoters) during
selection (4, 14) or a pre-exposure of cells to certain cytotoxic
agents before selection (12, 13). Emergence of drug-resistant
tumor cells during cytotoxic chemotherapy is one of the major
unsolved problems in cancer therapy. One potential way to de-
crease the incidence of gene amplification-mediated drug re-
sistance is to selectively accelerate the loss of newly acquired
unstably amplified genes from "nascent" drug-resistant cells.
Unlike amplified cellular genes in tumor cells, which may be
either stably or unstably amplified, chromosomes of certain DNA
viruses that transform mammalian cells exist virtually exclu-
sively in a free (unintegrated) form (40, 41). Among such viruses
are papilloma viruses and possibly certain types of Herpesvirus
(40). These viruses are associated with a wide variety of human
pathologic conditions including both benign and malignant neo-
plastic lesions (40, 41).
If hydroxyurea should affect the stability of extrachromo-
somal viral DNAs in a way analogous to its striking effect on
unstably amplified cellular genes, one could exploit the hy-
droxyurea effect for "curing" mammalian cells of extrachro-
mosomally maintained viral DNA genomes. It should be noted
in this regard that Turek et al. (40) have already shown that pro-
longed treatment of papilloma virus-transformed mouse cells
with interferon results in a significant decrease in the number
of extrachromosomal viral genomes per cell.
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